Latest Histone deacetylase Stories
HUYA holds exclusive rights to chidamide as HBI-8000 ex-China SAN DIEGO, Jan.
SHENZHEN, China, Jan.
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc.
Study to focus on mutations and deletions of CREBBP and EP300 genes in lymphomas SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc.
A new mouse study suggests that a class of drugs approved to treat leukemia and epilepsy also may be effective against kidney stones, researchers at Washington University School of Medicine in St. Louis report.
SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S.
Transparency Market Research has added a new report titled "Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to
Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia
Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients.
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.